Goldman Sachs has initiated coverage of MoonLake Immunotherapeutics (NASDAQ:MLTX) with a neutral rating, stating that it sees high potential for the company’s drug candidate sonelokimab in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results